PL2623497T3 - Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu - Google Patents
Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamiduInfo
- Publication number
- PL2623497T3 PL2623497T3 PL11829249T PL11829249T PL2623497T3 PL 2623497 T3 PL2623497 T3 PL 2623497T3 PL 11829249 T PL11829249 T PL 11829249T PL 11829249 T PL11829249 T PL 11829249T PL 2623497 T3 PL2623497 T3 PL 2623497T3
- Authority
- PL
- Poland
- Prior art keywords
- fluoro
- hydroxy
- meglumine salt
- pyrazine carboxamide
- pyrazine
- Prior art date
Links
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010221620 | 2010-09-30 | ||
| PCT/JP2011/072329 WO2012043696A1 (ja) | 2010-09-30 | 2011-09-29 | 6-フルオロ-3-ヒドロキシ-2-ピラジンカルボキサミドのメグルミン塩 |
| EP11829249.9A EP2623497B1 (en) | 2010-09-30 | 2011-09-29 | Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2623497T3 true PL2623497T3 (pl) | 2016-07-29 |
Family
ID=45893135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11829249T PL2623497T3 (pl) | 2010-09-30 | 2011-09-29 | Sól megluminowa 6-fluoro-3-hydroksy-2-pirazynokarboksamidu |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20130217708A1 (pl) |
| EP (1) | EP2623497B1 (pl) |
| JP (1) | JP5936546B2 (pl) |
| CN (1) | CN103209967B (pl) |
| CY (1) | CY1117218T1 (pl) |
| DK (1) | DK2623497T3 (pl) |
| ES (1) | ES2561878T3 (pl) |
| HR (1) | HRP20160218T1 (pl) |
| HU (1) | HUE026794T2 (pl) |
| MY (1) | MY161757A (pl) |
| PH (2) | PH12013500603A1 (pl) |
| PL (1) | PL2623497T3 (pl) |
| RS (1) | RS54642B1 (pl) |
| SG (1) | SG188662A1 (pl) |
| SI (1) | SI2623497T1 (pl) |
| SM (1) | SMT201600184B (pl) |
| TW (1) | TWI507397B (pl) |
| WO (1) | WO2012043696A1 (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778398B2 (en) | 2008-11-04 | 2014-07-15 | Jazz Pharmaceuticals, Inc. | Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| HRP20151263T1 (hr) | 2010-09-30 | 2015-12-18 | Toyama Chemical Co., Ltd. | Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida |
| AR095527A1 (es) | 2013-03-15 | 2015-10-21 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix |
| TWI700101B (zh) | 2014-03-24 | 2020-08-01 | 美商百歐維拉提夫治療公司 | 凍乾之因子ix調配物 |
| CN104610153B (zh) * | 2015-01-19 | 2017-02-22 | 沈阳中海生物技术开发有限公司 | 奥扎格雷葡甲胺盐及其组合物、制备方法和用途 |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| TW201808291A (zh) * | 2016-06-30 | 2018-03-16 | 富山化學工業股份有限公司 | 冷凍乾燥製劑之製造方法 |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US11679083B2 (en) | 2017-12-28 | 2023-06-20 | Fujifilm Toyama Chemical Co., Ltd. | Method for producing freeze-dried formulation |
| WO2020106735A1 (en) | 2018-11-19 | 2020-05-28 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| JP7553453B2 (ja) | 2019-03-01 | 2024-09-18 | フラメル アイルランド リミテッド | 食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物 |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| CN111214446B (zh) * | 2020-03-07 | 2022-02-25 | 瑞阳制药股份有限公司 | 一种供注射用法匹拉韦l-精氨酸盐冻干制剂 |
| CN114057656B (zh) * | 2020-08-05 | 2025-11-18 | 广东东阳光药业股份有限公司 | 一种法匹拉韦共晶及其制备方法 |
| CN114075145A (zh) * | 2020-08-14 | 2022-02-22 | 广东东阳光药业有限公司 | 一种法匹拉韦盐及其晶型和制备方法 |
| CN114159442B (zh) * | 2020-09-11 | 2025-03-25 | 盈科瑞(天津)创新医药研究有限公司 | 法匹拉韦在制备预防或治疗冠状病毒感染性疾病药物中的应用 |
| CN114159414B (zh) * | 2020-09-11 | 2025-03-04 | 盈科瑞(天津)创新医药研究有限公司 | 一种雾化吸入用法匹拉韦溶液及其制备方法 |
| WO2022076824A1 (en) | 2020-10-08 | 2022-04-14 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| CN113750105A (zh) * | 2020-12-11 | 2021-12-07 | 山东大学 | 一种法匹拉韦药用结合物及在制备抗病毒药物制剂中的应用 |
| CN116761591A (zh) * | 2020-12-18 | 2023-09-15 | 富士胶片富山化学株式会社 | 药物组合物 |
| JPWO2022131112A1 (pl) * | 2020-12-18 | 2022-06-23 | ||
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN121038779A (zh) | 2023-02-03 | 2025-11-28 | 特瑞斯制药公司 | 每晚一次的低钠羟丁酸盐组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4590269A (en) * | 1984-03-29 | 1986-05-20 | Syntex (U.S.A.) Inc. | Process for preparing the cyclic phosphate ester of substituted 9-(1,3-dihydroxy-2-propoxymethyl)purines |
| IT1207994B (it) * | 1986-01-03 | 1989-06-01 | Therapicon Srl | Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche. |
| JP3845876B2 (ja) * | 1995-04-20 | 2006-11-15 | アステラス製薬株式会社 | ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法 |
| AU736555B2 (en) | 1998-01-07 | 2001-08-02 | Meiji Seika Pharma Co., Ltd. | A composition comprising a crystallographically stable, amphorous cephalosporin and processes for the preparation thereof |
| ID28806A (id) | 1998-08-20 | 2001-07-05 | Toyama Chemical Co Ltd | Turunan-turunan karboksamida heterosiklik yang mengandung nitrogen atau garam-garam daripadanya dan zat-zat antivirus yang terdiri dari senyawa ini |
| KR100604955B1 (ko) | 2000-02-16 | 2006-07-26 | 토야마 케미칼 컴퍼니 리미티드 | 신규한 피라진 유도체 또는 그 염, 이를 함유하는 의약조성물, 및 그 제조 중간물 |
| DE10161077A1 (de) * | 2001-12-12 | 2003-06-18 | Boehringer Ingelheim Vetmed | Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion |
| PT1868581E (pt) * | 2005-04-11 | 2012-06-22 | Abbott Lab | Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis |
| BRPI0807597B8 (pt) | 2007-02-16 | 2021-05-25 | Fujifilm Toyama Chemical Co Ltd | composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação |
| JP5174365B2 (ja) * | 2007-03-23 | 2013-04-03 | 第一三共株式会社 | キノロン含有凍結乾燥製剤の製造方法 |
| EP2192117B1 (en) * | 2007-09-27 | 2014-06-04 | Toyama Chemical Co., Ltd. | Organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile and method for producing the same |
| TWI463999B (zh) | 2009-03-13 | 2014-12-11 | Toyama Chemical Co Ltd | 含有6-氟-3-羥基-2-吡羧醯胺之錠劑及粒狀粉末 |
| HRP20151263T1 (hr) * | 2010-09-30 | 2015-12-18 | Toyama Chemical Co., Ltd. | Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida |
-
2011
- 2011-09-29 US US13/877,037 patent/US20130217708A1/en not_active Abandoned
- 2011-09-29 HU HUE11829249A patent/HUE026794T2/en unknown
- 2011-09-29 EP EP11829249.9A patent/EP2623497B1/en active Active
- 2011-09-29 PL PL11829249T patent/PL2623497T3/pl unknown
- 2011-09-29 MY MYPI2013001091A patent/MY161757A/en unknown
- 2011-09-29 DK DK11829249.9T patent/DK2623497T3/en active
- 2011-09-29 JP JP2012536534A patent/JP5936546B2/ja active Active
- 2011-09-29 SI SI201130754T patent/SI2623497T1/sl unknown
- 2011-09-29 SG SG2013023353A patent/SG188662A1/en unknown
- 2011-09-29 ES ES11829249.9T patent/ES2561878T3/es active Active
- 2011-09-29 WO PCT/JP2011/072329 patent/WO2012043696A1/ja not_active Ceased
- 2011-09-29 PH PH1/2013/500603A patent/PH12013500603A1/en unknown
- 2011-09-29 HR HRP20160218T patent/HRP20160218T1/hr unknown
- 2011-09-29 CN CN201180055096.6A patent/CN103209967B/zh active Active
- 2011-09-29 TW TW100135204A patent/TWI507397B/zh active
- 2011-09-29 RS RS20160178A patent/RS54642B1/sr unknown
-
2014
- 2014-10-07 US US14/508,185 patent/US9090571B2/en active Active
-
2015
- 2015-06-09 US US14/734,263 patent/US20150266832A1/en not_active Abandoned
- 2015-06-15 PH PH12015501328A patent/PH12015501328B1/en unknown
-
2016
- 2016-02-23 CY CY20161100148T patent/CY1117218T1/el unknown
- 2016-06-16 SM SM201600184T patent/SMT201600184B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12013500603A1 (en) | 2015-10-23 |
| WO2012043696A1 (ja) | 2012-04-05 |
| HK1183014A1 (en) | 2013-12-13 |
| US9090571B2 (en) | 2015-07-28 |
| PH12015501328A1 (en) | 2015-09-21 |
| TWI507397B (zh) | 2015-11-11 |
| PH12015501328B1 (en) | 2015-09-21 |
| EP2623497B1 (en) | 2016-01-20 |
| ES2561878T3 (es) | 2016-03-01 |
| CN103209967B (zh) | 2015-04-08 |
| RS54642B1 (sr) | 2016-08-31 |
| US20150266832A1 (en) | 2015-09-24 |
| EP2623497A4 (en) | 2014-03-26 |
| EP2623497A1 (en) | 2013-08-07 |
| US20150031885A1 (en) | 2015-01-29 |
| MY161757A (en) | 2017-05-15 |
| SI2623497T1 (sl) | 2016-04-29 |
| CY1117218T1 (el) | 2017-04-05 |
| HUE026794T2 (en) | 2016-07-28 |
| TW201217343A (en) | 2012-05-01 |
| HRP20160218T1 (hr) | 2016-03-25 |
| DK2623497T3 (en) | 2016-03-21 |
| SG188662A1 (en) | 2013-05-31 |
| JP5936546B2 (ja) | 2016-06-22 |
| US20130217708A1 (en) | 2013-08-22 |
| SMT201600184B (it) | 2016-08-31 |
| JPWO2012043696A1 (ja) | 2014-02-24 |
| CN103209967A (zh) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2623497T1 (sl) | Megluminska sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida | |
| SI2623498T1 (sl) | Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida | |
| IL259958B (en) | Heterocyclic glutaminase inhibitors | |
| ZA201303793B (en) | Substituted quinoline compounds and methods of use | |
| IL237581B (en) | Derivatives of 6-oxo-pyrazinopyrrolopyrimidines | |
| IL222227A0 (en) | Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use | |
| ZA201209205B (en) | Pyridone and aza-pyridone compounds and methods of use | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| ZA201303586B (en) | Salts and crystalline forms of an apoptosis-inducing agent | |
| IL232599A (en) | Hydrobromide salt of peridofidine | |
| ZA201209407B (en) | Modification of xylan | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| AP3268A (en) | Co-crystals and salts of CCR3-inhibitors | |
| GB201111396D0 (en) | Monitoring of livestock | |
| PL2753330T3 (pl) | Terapeutyczne zastosowania ektoiny | |
| EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
| ZA201209666B (en) | Salts and polymorhs of dexrabeprazole | |
| EP2601178A4 (en) | SALTS OF LAPATINIB | |
| GB201021179D0 (en) | Monitoring of clearance | |
| GB201117252D0 (en) | Improved treatment of hard surfaces | |
| IL243320A0 (en) | Intermediates of teroarylpiperidine and piperazine derivatives | |
| HU1000688D0 (en) | Use of trifluoro-phal | |
| GB201004480D0 (en) | Therapeutic use of new compounds II | |
| GB201017798D0 (en) | Nlec as an inhibitor of NFKB activity | |
| GB201009614D0 (en) | Therapeutic use of compounds |